– Nanofluidic tau aggregation within seconds
About the technology
The availability of tau protein aggregates in vitro is essential for drug development and Alzheimer’s research, but is hampered by limitations in protein aggregation techniques. The slow aggregation process of tau into fibrils can take up to 2 months. With our new technology we can produce oligomers and fibrils within seconds in a nanofluidic environment without chemical addition of heparin. Our method can provide tau aggregates “on-demand” for high throughput screening of drug candidates, automated in-vitro assays and for binding assays at single molecule sensitivity.
Value proposition
- Induced tau oligomerisation events in seconds
- Single molecule sensitivity
- Observing interactions of other biomolecules possible (screening of aggregation inhibitors, antibodies, etc.)
- Low consumption of:
- Power
- Sample
- Time
Areas of application
We envisage producing our nanofluidic Tau-on- Chip devices for use in drug development, clinical trials, research, and protein production.
Resources and partners
Research Council Norway commercialisation grant submission by end 2022 Patent filing expected early 2023 Norinnova as commercialisation partner
Opportunities for Collaboration
We are looking for industry partners for collaboration and licensing. We are open for working together on the development of our Tau-on-Chip technology to accomodate your needs.
Contact information
Ellen Dybdahl
Business developer, Norinnova
ellen@norinnova.no
Phone: +47 974 79 260
Lars Sørensen
wkefkjbefkjbkwebskj
The Inventors
Lars Sørensen
Magnus Seppola
Ingrid Skjæveland
We are looking for industry partners for collaboration and licensing. We are open for working together on the development of our Tau-on-Chip technology to accomodate your needs.
Opportunities for Collaboration
We are looking for industry partners for collaboration and licensing. We are open for working together on the development of our Tau-on-Chip technology to accomodate your needs.